Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma

Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6–NTRK fusion, which constitutively activates the tropomyosin‐related kinase (TRK) signaling pathway. Larotrectinib is a highly selective TRK inhibitor with activity i...

Full description

Saved in:

Bibliographic Details
Published in:	Pediatric blood & cancer Vol. 65; no. 10; pp. e27271 - n/a
Main Authors:	Halalsheh, Hadeel, McCarville, Mary Beth, Neel, Michael, Reynolds, Mark, Cox, Michael C., Pappo, Alberto S.
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 01.10.2018
Subjects:	bone metastasis Bone remodeling ETV6–NTRK Hematology Infants larotrectinib mesoplastic nephroma Metastases Neonates Oncology Pediatrics Signal transduction TRK inhibitor Tropomyosin mesoplastic nephroma larotrectinib bone metastasis ETV6-NTRK TRK inhibitor
ISSN:	1545-5009, 1545-5017, 1545-5017
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!